



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4009318>Available online at: <http://www.iajps.com>

Research Article

**RECOGNITION OF POSITIVITY AND PREVALENCE OF
ANTINUCLEAR ANTIBODIES IN CHILDHOOD RHEUMATIC
DISEASES****Dr Muhammad Azam Bakhtawar¹, Dr Farhad², Dr Nureen Shahzadee³**¹Shaikh Khalifa bin Zayed Al- Nahyan Medical and Dental College, Lahore, ²Mayo Hospital, Lahore, ³Woman Medical Officer, Indus Hospital.**Article Received:** June 2020**Accepted:** July 2020**Published:** August 2020**Aim:** To determine the positivity and prevalence of ANA in various autoimmune diseases in children.**Patients and Methods:** This was a cross-sectional observational study conducted at the Departments of Pediatric Medicine, Immunology and Serology, Services Hospital Lahore for one-year duration from April 2019 to April 2020. More than 200 blood samples were taken from various medical departments and serology for ANA Elisa tests was also performed. Of these, only ANA positive patients were selected. Pre-designed pro-form information and data were analyzed by SPSS version 16.**Results:** Of the 200 patients, 45 (22.5%) were ANA positive. Of 45 ANA positive patients, 25 (55.6%) had a diagnosis of SLE, 9 (20%) had MCTD, 5 (11.1%) had scleroderma, 4 (8.9%) had dermatomyositis, 2 (4.4%) had polymyositis. There was also a female advantage with a female to male ratio of 3: 1.2. The age of the studied population ranged from 3 (minimum) to 16 (maximum) years with an average age of 10.29 ± 3.80 years.**Conclusion:** The ANA Elisa test can be used as a screening tool for clinically suspected rheumatic diseases in children.**Key words:** Antinuclear antibodies, systemic lupus erythematosus, mixed connective tissue disease.**Corresponding author:****Dr. Muhammad Azam Bakhtawar,**

Shaikh Khalifa bin Zayed Al- Nahyan Medical and Dental College, Lahore.

QR code



Please cite this article in press Muhammad Azam Bakhtawar et al *Recognition Of Positivity And Prevalence Of Antinuclear Antibodies In Childhood Rheumatic Diseases., Indo Am. J. P. Sci, 2020; 07(08).*

INTRODUCTION:

Childhood rheumatic diseases are complex chronic diseases that are clinical symptoms of connective tissue of the musculoskeletal system, blood vessels and skin. They are rare in children, and when they do occur, they can be difficult to diagnose and difficult to treat. Rheumatic diseases are widespread worldwide, although there are significant differences in the prevalence of the same diseases between different racial groups [1-2]. The extent of childhood rheumatic diseases in certain populations was difficult to determine with any accuracy. The most common rheumatic diseases included juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), dermatomyositis, scleroderma, and juvenile idiopathic arthritis (JIA) [3-4]. The combination of genetic predisposition and environmental factors contributes to the development of autoimmune diseases. Many autoimmune diseases begin relatively young and continue throughout life. They have a disproportionate impact on public health, with an estimated annual cost of over \$ 100 billion in the United States alone [5-6]. In addition, most autoimmune diseases are chronic in nature and require lifelong care. Autoimmune diseases affect 8% of the population, 78% of whom are women. Antinuclear antibodies (ANA) - Nuclear autoantibodies are a diverse group of antibodies that react to nuclear, nuclear, or perinuclear antigens. These antigens represent cellular components such as nucleic acid, histone, chromatin, nuclear and ribonuclear proteins. Classically, ANA is characterized by a serological diagnosis of SLE and is included in the American College of Rheumatology's SLE classification criteria, but finding ANA is common to most other autoimmune diseases [7-8]. There are many reports of the prevalence of ANA in serum in healthy adults and children. The presence of autoantibodies in a patient does not guarantee the diagnosis of an autoimmune disease. Rather, a positive serological test combined with the relevant symptoms and signs helps in the diagnosis. In the past, many different methods have been used to test for the presence of autoantibodies [9-10]. Currently, tests are mainly performed with enzyme immunosorbent assays

(EIAs) due to cost-saving measures related to mechanization. Typically, screening a patient's serum for ANA with an ELISA assay provides a high degree of sensitivity.

PATIENTS AND METHODS:

This study was conducted at the Departments of Pediatric Medicine and Immunology and Serology of the Services Hospital Lahore for one-year duration from April 2019 to April 2020. All patients aged 1 to 16 years clinically suspected of having rheumatic disease were included in the study. Under aseptic conditions, trained personnel collected 3 ml of venous blood from patients, marked them with appropriate numbers and sent them to the Department of Immunology and Serology for ANA Elisa tests. The ORGENTEC ANA Detect test is intended for a qualitative enzyme immunoassay (EIA) to test for the presence of antinuclear antibodies (ANA) in serum. Detection of ANA Elisa was negative when <1.0, border between 1.0-1.2, positive when > 1.2. The demographics and clinical presentation of these patients have been recorded. All data was recorded in a previously designed proforma and the results were analyzed using SPSS version 16. The mean \pm SD is given for quantitative variables. Frequencies and percentages for qualitative variables are given.

RESULTS:

A total of 200 patients participated. Of these, 45 (22.5%) were ANA positive and were included in the study for further analysis. ANA Elisa titers range from 1.22 to 6.20 with a mean of 2.87 \pm 0.886. There were 33 (73.3%) women and 12 (26.7%) men with a K: M 3: 1 ratio. The mean age at the time of the study was 10.29 \pm 3.8 years, with a minimum age of 3 years and a maximum of 16 years. Six patients (13.3%) were aged 1 to 5 years, 19 (42.2%) were aged 6 to 10 years, and 20 (44.5%) were aged 11 to 16 years. SLE was the most common ANA positive autoimmune disease (n = 25, 55.6%), followed by mixed comorbid disease, scleroderma, dermatomyositis, and polymyositis. (Table 1)

Table 1: Frequency of Rheumatic diseases among ANA positive study group (n=45)

Autoimmune Diseases	=n	%age
Systemic Lupus Erythematosus	25	55.6
Scleroderma	05	11.1
Dermatomyositis	04	8.9
Mixed Connective Tissue Disease	09	20
Polymyositis.	02	4.4

The most common clinical symptom was rash (discoid lupus, buccal rash, heliotropic rash, vascular rash) in

42 (93.3%), followed by photosensitivity (88.9%), jaundice (68.9%) , kidney involvement (66.7%) and

arthritis (60%), Raynaud's phenomenon (42.2%), mouth and nose ulcers (33.3%), muscle weakness (17.8%) and scleroderma (24, 4%) (Table 2).

Table 2. Clinical findings of Antinuclear antibodies positive patients (n=45)

Clinical presentation	=n	%age
Rash*	42	93.33
Photosensitivity	40	88.89
Arthritis	27	60.00
Oral and/or Nasal ulcers	15	33.33
Jaundice	31	68.89
Renal involvement	30	66.67
Raynaud phenomenon	19	42.22
muscle weakness	08	17.78
scleroderma changes	11	24.44

DISCUSSION:

Antinuclear antibody (ANA) tests are often used to screen children for rheumatic diseases in childhood. However, the diagnostic utility of this test is limited due to the large number of healthy children positive for low titer tests [9-10]. In our study, the ANA test was performed on 200 patients with clinical suspicion of some autoimmune rheumatic disease, but the result was positive in 45 (22.5%) patients. Indeed, Malleon and colleagues showed that the ANA test can be positive in up to 33% of healthy children. Other studies have confirmed the lack of specificity of the ANA test in children. The most common autoimmune rheumatic disease in our study was SLE, which was found in 25 (55.6%) patients [11-12]. Due to the variety of clinical images with which childhood SLE is presented, it is often found in the differential diagnosis of children with difficult or difficult diseases [13-14]. The antinuclear antibodies were positive in 95-99% of people with SLE. Although a positive ANA is not required for a diagnosis of SLE, yet a negative ANA is extremely rare in SLE. Most of our patients are women over the age of 8. Lehman et al. Reported the same findings in their studies. Because most of the patients in our study suffered from SLE, which most often manifests as rash, photosensitivity, arthritis, and mouth ulcers. This is in line with many other studies [15]. Children with autoimmune rheumatic diseases are often clinically indistinguishable from other ANA-positive children for the conditions with which they present to initial care. However, judicious use of history, physical examination, and thoughtful interpretation of the ANA titer will greatly help differentiate children with these conditions from children with milder conditions.

CONCLUSION:

ANA Elisa titers help distinguish children with autoimmune rheumatic diseases from children with

other conditions. Patient age, gender, and ANA titer are the best measures to distinguish children with autoimmune diseases from ANA-positive children with other diseases or self-limited conditions. Due to the limited diagnostic specificity and high incidence of false positives, the ANA test should only be used when clinical testing suggests some autoimmune rheumatic disease.

REFERENCES:

1. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, Chan EK, Miller FW. Increasing Prevalence of Antinuclear Antibodies in the United States. *Arthritis & Rheumatology*. 2020 Apr 7.
2. Islam MI, Laila K, Rahman SA. Pattern and Frequency of Anti-nuclear Antibody Positivity in Paediatric Rheumatic Diseases. *Bangladesh Journal of Child Health*. 2019 Apr 28;43(1):21-6.
3. Hayworth JL, Turk MA, Nevskaya T, Pope JE. The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. *Joint Bone Spine*. 2019 Nov 1;86(6):685-90.
4. Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F. Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohort database. *Joint bone spine*. 2019 May 1;86(3):343-50.
5. Almeida RM, da Silva ZD, Leite FB, de Medeiros Nóbrega YK. Antinuclear Antibodies Patterns in Patients with Celiac Disease. *Biomed. J*. 2019;1(3).
6. Im JH, Chung MH, Park YK, Kwon HY, Baek JH, Lee SY, Lee JS. Antinuclear antibodies in infectious diseases. *Infectious Diseases*. 2020 Mar 3;52(3):177-85. Im, J.H., Chung, M.H., Park, Y.K., Kwon, H.Y., Baek, J.H., Lee, S.Y. and Lee,

- J.S., 2020. Antinuclear antibodies in infectious diseases. *Infectious Diseases*, 52(3), pp.177-185.
7. de Gruijter NM, Naja M, Peckham H, Radziszewska A, Kinsella M, Glenister J, Rosser E, Butler GE, Jury EC, Ciurtin C. A systematic review exploring the bidirectional relationship between puberty and autoimmune rheumatic diseases.
 8. Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: an update. *Clinical Reviews in Allergy & Immunology*. 2020 Feb 1;58(1):40-51.
 9. Aygün E, Kelesoglu FM, Dogdu G, Ersoy A, Basbug D, Akça D, Çam ÖN, Akyüz B, Günsay T, Kapici AH, Aydın NG. Antinuclear antibody testing in a Turkish pediatrics clinic: is it always necessary?. *The Pan African Medical Journal*. 2019;32.
 10. Fonseca A, Rodrigues M, Sztajn bok FR, Land M, Oliveira SK. AB0969 COMPARISON AMONG ACR1997, SLICC AND THE NEW EULAR/ACR CLASSIFICATION CRITERIA IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS.
 11. Rodríguez S, Muñoz A, Bustos RH, Jaimes D. Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. *Biomedicines*. 2020 Sep;8(9):303.
 12. Cavalcante MB, Cavalcante CT, Sarno M, da Silva AC, Barini R. Antinuclear antibodies and recurrent miscarriage: Systematic review and meta-analysis. *American Journal of Reproductive Immunology*. 2020 Mar;83(3):e13215.
 13. Skare TL, Neppel A, Machoski MC, Maestri CA, Messias-Reason I, Nisihara R. Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer. *Immunology letters*. 2019 Apr 1;208:8-10.
 14. Skare TL, Neppel A, Machoski MC, Maestri CA, Messias-Reason I, Nisihara R. Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer. *Immunology letters*. 2019 Apr 1;208:8-10.
 15. Wang YM, Yu YF, Liu Y, Liu S, Hou M, Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. *Hematology*. 2020 Jan 1;25(1):139-44. Wang YM, Yu YF, Liu Y, Liu S, Hou M, Liu XG. The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. *Hematology*. 2020 Jan 1;25(1):139-44.